Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazue Kasai

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Current Gene Therapy|June 22, 2006
DNA-based methods to prepare helper virus-free herpes amplicon vectors and versatile design of amplicon vector plasmidsKazue Kasai, Yoshinaga Saeki
Journal of Virology|March 16, 2006
Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatinMasataka Suzuki, Kazue Kasai, Yoshinaga Saeki
ILAR Journal|April 2, 2016
Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes VirusesMaria-Carmela Speranza, Kazue Kasai, Sean E Lawler
The Journal of Biological Chemistry|February 8, 2007
Neural expression of G protein-coupled receptors GPR3, GPR6, and GPR12 up-regulates cyclic AMP levels and promotes neurite outgrowthShigeru Tanaka, Ken Ishii, Kazue Kasai, et al.
Molecular Therapy. Methods & Clinical Development|May 7, 2020
Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence GeneE Antonio Chiocca, Hiroshi Nakashima, Kazue Kasai, et al.
Developmental Biology|June 9, 2009
Four distinct phases of basket/stellate cell migration after entering their final destination (the molecular layer) in the developing cerebellumD Bryant Cameron, Kazue Kasai, Yulan Jiang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 12, 2017
Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic VirusesAkihiro Otsuki, Ankita Patel, Kazue Kasai, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 24, 2008
Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic virusesAkihiro Otsuki, Ankita Patel, Kazue Kasai, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 19, 2009
ICP0 inhibits the decrease of HSV amplicon-mediated transgene expressionMasataka Suzuki, Kazue Kasai, Akihiro Ohtsuki, et al.
Molecular Therapy. Nucleic Acids|August 8, 2013
Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with ProdrugsKazue Kasai, Hiroshi Nakashima, Fang Liu, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Current Gene Therapy|June 22, 2006
DNA-based methods to prepare helper virus-free herpes amplicon vectors and versatile design of amplicon vector plasmidsKazue Kasai, Yoshinaga Saeki
Journal of Virology|March 16, 2006
Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatinMasataka Suzuki, Kazue Kasai, Yoshinaga Saeki
ILAR Journal|April 2, 2016
Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes VirusesMaria-Carmela Speranza, Kazue Kasai, Sean E Lawler
The Journal of Biological Chemistry|February 8, 2007
Neural expression of G protein-coupled receptors GPR3, GPR6, and GPR12 up-regulates cyclic AMP levels and promotes neurite outgrowthShigeru Tanaka, Ken Ishii, Kazue Kasai, et al.
Molecular Therapy. Methods & Clinical Development|May 7, 2020
Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence GeneE Antonio Chiocca, Hiroshi Nakashima, Kazue Kasai, et al.
Developmental Biology|June 9, 2009
Four distinct phases of basket/stellate cell migration after entering their final destination (the molecular layer) in the developing cerebellumD Bryant Cameron, Kazue Kasai, Yulan Jiang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 12, 2017
Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic VirusesAkihiro Otsuki, Ankita Patel, Kazue Kasai, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 24, 2008
Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic virusesAkihiro Otsuki, Ankita Patel, Kazue Kasai, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 19, 2009
ICP0 inhibits the decrease of HSV amplicon-mediated transgene expressionMasataka Suzuki, Kazue Kasai, Akihiro Ohtsuki, et al.
Molecular Therapy. Nucleic Acids|August 8, 2013
Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with ProdrugsKazue Kasai, Hiroshi Nakashima, Fang Liu, et al.
Pageof 2